GHK-Cu and peppers for skin glow: what the science says
Quick answer
This video presents five compounds with highly variable evidence profiles and regulatory statuses as a cohesive 'glow up' stack, without distinguishing between FDA-approved drugs used off-label (Tesamorelin), investigational Phase 2 compounds (Retatrutide), peptides with strong preclinical but weak human data (BPC-157), and compounds with legitimate cosmetic research (GHK-Cu). The FDA's 2023 compounding guidance specifically restricts BPC-157 from regulated compounding channels, a fact directly relevant to any consumer trying to source this stack legally. Patients interested in any of these compounds should consult a licensed provider who can assess individual metabolic health, review contraindications, and source through verified regulated channels.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @hannahlang49 actually say?
The creator rattled off five compounds she'd take "before summer" for aesthetics and fat loss: GHK-Cu for skin and hair, "Tess and Marilyn" (almost certainly Tesamorelin) for belly fat, NAD+ for cellular energy, BPC-157 for gut health and recovery, and "redder" (almost certainly Retatrutide) as the top pick for fat loss and blood sugar control. She closed with a disclaimer that this is "for research and educational purposes only" and told viewers to consult a physician. That disclaimer does real work here, because several of these compounds carry significant regulatory and safety caveats that a 60-second list format cannot adequately convey.
She also offered a PDF "stack guide" to anyone who comments. Selling or distributing peptide dosing guides through social media, even framed as educational, sits in genuinely murky territory under FTC and FDA guidelines.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
BPC-157 access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GHK-Cu and peppers for skin glow: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
EGRIFTA (tesamorelin for injection) FDA Prescribing Information
FDA-approved label for tesamorelin (NDA 022505), indicated to reduce excess abdominal fat in HIV patients with lipodystrophy.
FDA
Egrifta (tesamorelin) Original NDA 022505 FDA Approval Letter
FDA approval letter marking the first approved drug for HIV-associated lipodystrophy.
FDA
Provider decision path
Use local research to choose a safer review path
Direct answer
BPC-157 is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this bpc-157 video claims cluster
Best for searchers trying to separate BPC-157 research signals from overconfident recovery claims.
Claim verdict
The useful answer behind this video
Claim being checked
This video presents five compounds with highly variable evidence profiles and regulatory statuses as a cohesive 'glow up' stack, without distinguishing between FDA-approved drugs used off-label (Tesamorelin), investigational Phase 2 compounds (Retatrutide), peptides with strong preclinical but weak human data (BPC-157), and compounds with legitimate cosmetic research (GHK-Cu).
FormBlends verdict
This video presents five compounds with highly variable evidence profiles and regulatory statuses as a cohesive 'glow up' stack, without distinguishing between FDA-approved drugs used off-label (Tesamorelin), investigational Phase 2 compounds (Retatrutide), peptides with strong preclinical but weak human data (BPC-157), and compounds with legitimate cosmetic research (GHK-Cu). The FDA's 2023 compounding guidance specifically restricts BPC-157 from regulated compounding channels, a fact directly relevant to any consumer trying to source this stack legally. Patients interested in any of these compounds should consult a licensed provider who can assess individual metabolic health, review contraindications, and source through verified regulated channels.
Patient-safe next step
Compare the claim with the BPC-157 guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video presents five compounds with highly variable evidence profiles and regulatory statuses as a cohesive 'glow up' stack, without distinguishing between FDA-approved drugs used off-label (Tesamorelin), investigational Phase 2 compounds (Retatrutide), peptides with strong preclinical but weak human data (BPC-157), and compounds with legitimate cosmetic research (GHK-Cu). The FDA's 2023 compounding guidance specifically restricts BPC-157 from regulated compounding channels, a fact directly relevant to any consumer trying to source this stack legally. Patients interested in any of these compounds should consult a licensed provider who can assess individual metabolic health, review contraindications, and source through verified regulated channels.
- Tesamorelin has exactly one FDA-approved use: HIV-associated lipodystrophy. Off-label use in metabolically healthy adults is not supported by the same evidence.
- BPC-157 was removed from FDA-permitted compounding substances in 2023, meaning sourcing it through a licensed compounding pharmacy in the US is no longer straightforward.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- BPC-157 decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the BPC-157 guide, cost path, safety notes, and provider review before acting.
Review BPC-157What You'll Learn
- Tesamorelin has exactly one FDA-approved use: HIV-associated lipodystrophy. Off-label use in metabolically healthy adults is not supported by the same evidence.
- BPC-157 was removed from FDA-permitted compounding substances in 2023, meaning sourcing it through a licensed compounding pharmacy in the US is no longer straightforward.
- Retatrutide showed 17.5% weight reduction in a 2023 Phase 2 NEJM trial, but it has no approved indication and is classified as an investigational drug, not a consumer peptide.
- GHK-Cu has the strongest cosmetic evidence of the five, with peer-reviewed dermatology data on collagen synthesis, though most studies involve topical use rather than systemic administration.
- NAD+ precursors (NMN, NR) have more human clinical data than direct injectable NAD+, which has minimal randomized controlled trial evidence in healthy adults.
- Offering a peptide 'stack guide' PDF via social media comments, even with an educational disclaimer, raises FTC and FDA regulatory concerns around unlicensed health guidance.
- The 'research purposes only' disclaimer does not reduce biological risk from impure or misdosed compounds sourced outside regulated channels.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Han | Performance Coach · TikTok creator
28.2K views on this video
The 5 Ultimate Peppers if you’re wanting to GLOW up 💁🏼♀️ #peppers #ghkcu #bpc157benefits #glowup #biohacking
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Han | Performance Coach, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.